EffEx-HN trial: study protocol for a randomized controlled trial on the EFFectiveness and feasibility of a comprehensive supervised EXercise program during radiotherapy in Head and Neck cancer patients on health-related quality of life.
Cancer rehabilitation
Effectiveness
Exercise
Feasibility
Head and neck cancer
Quality of life
Radiotherapy
Tele-coaching
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
15 Apr 2023
15 Apr 2023
Historique:
received:
05
12
2022
accepted:
14
02
2023
medline:
18
4
2023
entrez:
15
4
2023
pubmed:
16
4
2023
Statut:
epublish
Résumé
With over 500,000 annually reported cases worldwide, head and neck cancer (HNC) is the seventh most common type of cancer worldwide. Treatment of HNC with chemoradiotherapy frequently results in serious impairments in physical and psychosocial functioning. Besides, HNC patients typically start their cancer treatment already with poor physical and psychosocial health. It has been shown that a sufficient level of physical activity (PA) before, during, and after cancer treatment is associated with fewer negative treatment-related side effects and a better quality of life (QOL). In order to prevent worsening of functioning and limit the physical impact of the HNC treatment, a comprehensive supervised exercise program (CSEP) may be beneficial during early cancer treatment. However, up to now, the feasibility and effectiveness of such a program are not yet investigated thoroughly in HNC. Therefore, the primary objective of this study is to examine the effectiveness of a CSEP during HNC treatment, in addition to usual supportive care, compared to usual supportive care alone, on health-related QOL up to 1 year post-diagnosis. Secondary objectives entail gathering information on (1) the effectiveness of a CSEP on secondary outcomes such as physical and mental function, activities of daily life, and participation in society and (2) the feasibility, possible barriers, and facilitators for participation in a CSEP during HNC treatment. To investigate the effectiveness of the CSEP, a parallel, open-label randomized controlled trial will be performed. To study the feasibility of the CSEP, a mixed-method study will be performed in a subgroup of participants. HNC patients are eligible if they receive radiotherapy at the Radiation-Oncology department of the University Hospital of Leuven. A 4-size permuted block randomization will be used. The control group receives the current standard of supportive care. The intervention group receives a CSEP, additional to the same usual supportive care. The CSEP consists of a 12-week intensive phase with 3 exercise sessions of 1 h per week, where supervision is gradually reduced after 6 weeks. During the maintenance phase (from week 13), patients exercise at home with monthly tele-consultations with a physiotherapist. The CSEP contains supervised aerobic and resistance training. In both groups, outcomes of interest are evaluated through self-reported questionnaires and clinical assessments, at baseline, 6 weeks, 12 weeks, 6 months, and 12 months post-diagnosis. The primary endpoint is health-related QOL, measured with the EORTC QLQ-C30 at 6 months post-diagnosis. The study will be conducted in accordance with the Declaration of Helsinki. This protocol has been approved by the ethical committee of the University Hospitals Leuven (s65549). Recruitment started in January 2022. Results will be disseminated via peer-reviewed scientific journals and presentations at congresses. Trial Registration: ClinicalTrials.gov Identifier: NCT05256238 Date of registration: February 25, 2022.
Sections du résumé
BACKGROUND
BACKGROUND
With over 500,000 annually reported cases worldwide, head and neck cancer (HNC) is the seventh most common type of cancer worldwide. Treatment of HNC with chemoradiotherapy frequently results in serious impairments in physical and psychosocial functioning. Besides, HNC patients typically start their cancer treatment already with poor physical and psychosocial health. It has been shown that a sufficient level of physical activity (PA) before, during, and after cancer treatment is associated with fewer negative treatment-related side effects and a better quality of life (QOL). In order to prevent worsening of functioning and limit the physical impact of the HNC treatment, a comprehensive supervised exercise program (CSEP) may be beneficial during early cancer treatment. However, up to now, the feasibility and effectiveness of such a program are not yet investigated thoroughly in HNC. Therefore, the primary objective of this study is to examine the effectiveness of a CSEP during HNC treatment, in addition to usual supportive care, compared to usual supportive care alone, on health-related QOL up to 1 year post-diagnosis. Secondary objectives entail gathering information on (1) the effectiveness of a CSEP on secondary outcomes such as physical and mental function, activities of daily life, and participation in society and (2) the feasibility, possible barriers, and facilitators for participation in a CSEP during HNC treatment.
METHODS
METHODS
To investigate the effectiveness of the CSEP, a parallel, open-label randomized controlled trial will be performed. To study the feasibility of the CSEP, a mixed-method study will be performed in a subgroup of participants. HNC patients are eligible if they receive radiotherapy at the Radiation-Oncology department of the University Hospital of Leuven. A 4-size permuted block randomization will be used. The control group receives the current standard of supportive care. The intervention group receives a CSEP, additional to the same usual supportive care. The CSEP consists of a 12-week intensive phase with 3 exercise sessions of 1 h per week, where supervision is gradually reduced after 6 weeks. During the maintenance phase (from week 13), patients exercise at home with monthly tele-consultations with a physiotherapist. The CSEP contains supervised aerobic and resistance training. In both groups, outcomes of interest are evaluated through self-reported questionnaires and clinical assessments, at baseline, 6 weeks, 12 weeks, 6 months, and 12 months post-diagnosis. The primary endpoint is health-related QOL, measured with the EORTC QLQ-C30 at 6 months post-diagnosis.
DISCUSSION
CONCLUSIONS
The study will be conducted in accordance with the Declaration of Helsinki. This protocol has been approved by the ethical committee of the University Hospitals Leuven (s65549). Recruitment started in January 2022. Results will be disseminated via peer-reviewed scientific journals and presentations at congresses.
TRIAL REGISTRATION
BACKGROUND
Trial Registration: ClinicalTrials.gov Identifier: NCT05256238 Date of registration: February 25, 2022.
Identifiants
pubmed: 37061715
doi: 10.1186/s13063-023-07170-x
pii: 10.1186/s13063-023-07170-x
pmc: PMC10105412
doi:
Banques de données
ClinicalTrials.gov
['NCT05256238']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
276Informations de copyright
© 2023. The Author(s).
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Lancet. 2021 Dec 18;398(10318):2289-2299
pubmed: 34562395
Br J Sports Med. 2016 Mar;50(6):325-38
pubmed: 25966911
Epidemiol Rev. 2017 Jan 1;39(1):59-70
pubmed: 28453627
J Clin Epidemiol. 2014 May;67(5):516-26
pubmed: 24698295
Res Nurs Health. 2000 Aug;23(4):334-40
pubmed: 10940958
Cancer. 2017 Jan 1;123(2):327-335
pubmed: 27696377
J Psychol. 2005 Sep;139(5):439-57
pubmed: 16285214
Int J Environ Res Public Health. 2018 Oct 03;15(10):
pubmed: 30282898
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Physiotherapy. 2017 Jun;103(2):222-230
pubmed: 27908458
Semin Hematol. 1997 Jul;34(3 Suppl 2):13-9
pubmed: 9253779
Harefuah. 2008 Jul;147(7):611-7, 662, 661
pubmed: 18814521
Med Sci Sports Exerc. 2019 Nov;51(11):2375-2390
pubmed: 31626055
Complement Ther Med. 2019 Jun;44:9-13
pubmed: 31126580
PLoS One. 2020 May 18;15(5):e0233395
pubmed: 32421740
Lymphat Res Biol. 2021 Jun;19(3):240-248
pubmed: 33181059
Gynecol Oncol. 2015 Aug;138(2):398-404
pubmed: 26026737
Int J Environ Res Public Health. 2021 Sep 08;18(18):
pubmed: 34574402
J Clin Densitom. 2020 Jul - Sep;23(3):443-450
pubmed: 30472111
Am J Prev Med. 1996 Mar-Apr;12(2):73-81
pubmed: 8777071
Ann Oncol. 2013 Feb;24(2):454-462
pubmed: 22910842
CA Cancer J Clin. 2019 Nov;69(6):468-484
pubmed: 31617590
Head Neck. 2016 Apr;38 Suppl 1:E1086-96
pubmed: 26445898
Lymphology. 2018;51(3):109-118
pubmed: 30422433
Ann Acad Med Singap. 1994 Mar;23(2):129-38
pubmed: 8080219
Laryngorhinootologie. 2018 Mar;97(S 01):S48-S113
pubmed: 29905354
Int J Behav Nutr Phys Act. 2011 Oct 21;8:115
pubmed: 22018588
Support Care Cancer. 2019 Oct;27(10):3913-3920
pubmed: 30919154
Lymphat Res Biol. 2021 Dec;19(6):562-567
pubmed: 33529086
Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):1013-8
pubmed: 12605981
Disabil Rehabil. 2007 Oct 15;29(19):1502-9
pubmed: 17852246
Head Neck. 2019 Jun;41(6):1725-1737
pubmed: 30636188
Disabil Rehabil. 2019 Aug;41(17):2093-2107
pubmed: 29976091
Ann Rheum Dis. 2004 Apr;63(4):335-41
pubmed: 15020324
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Med Sci Sports Exerc. 2019 Nov;51(11):2391-2402
pubmed: 31626056
Med Sci Sports Exerc. 2018 Sep;50(9):1790-1801
pubmed: 29683922
Clin Physiol Funct Imaging. 2021 Jul;41(4):317-325
pubmed: 33752260
J Med Internet Res. 2014 Mar 06;16(3):e74
pubmed: 24610383
Physiother Theory Pract. 2018 Mar;34(3):202-211
pubmed: 29068767
Semin Radiat Oncol. 2018 Jan;28(1):64-74
pubmed: 29173757
Rehabil Oncol. 2014;32(1):13-21
pubmed: 25346950